Federal Register / Vol. 89, No. 27 / Thursday, February 8, 2024 / Notices 8689 

3-Chloromethcathinone (3-CMC) 

(chemical name: 1-(3-chlorophenyl)-2- 

(methylamino)propan-1-one) is a 

synthetic cathinone that functions to 

inhibit reuptake of the dopamine, 

serotonin, and norepinephrine 

transporters in the central nervous 

system. Functionally this increases the 

concentration of these neurotransmitters 

which leads to psychostimulatory 

effects. Humans and animals have 

demonstrated clinical signs of agitation, 

restlessness, seizures, high blood 

pressure, and increased locomotor 

activity. The appearance of 3-CMC on 

the illicit drug market is similar to other 

designer drugs trafficked for their 

psychoactive effects. There are no 

commercial or approved medical uses 

for 3-CMC in the United States. 

Methcathinone was controlled in 

Schedule I of the CSA on October 15, 

1993. As a positional isomer of 

methcathinone, 3-CMC is controlled in 

Schedule I of the CSA. As such, 

additional permanent controls will not 

be needed if 3-CMC is placed in 

Schedule II of the Convention on 

Psychotropic Substances, 1971. 

Dipentylone (chemical name: 1-(1,3- 

benzodioxol-5-yl)-2- 

(dimethylamino)pentan-1-one, also 

known as N,N-dimethylpentylone, 

dimethylpentylone or bk-DMBDP) is a 

synthetic cathinone that produces 

psychostimulant effects similar to 

cathinone. Dipentylone functions by 

increasing the concentration of 

dopamine, serotonin, and 

norepinephrine in the central nervous 

system similar to amphetamines. 

Anecdotal reports indicate that 

dipentylone produces clinical effects of 

insomnia, hallucinations, paranoia, and 

confusion. As of 2021, dipentylone was 

identified in 8,368 drug seizures, and 

was confirmed as the cause of death in 

at least nine fatalities in 2023. There are 

no commercial or approved medical 

uses for dipentylone in the United 

States. Pentylone was controlled in 

Schedule I of the CSA on March 4, 2016. 

As a positional isomer of pentylone, 

dipentylone is controlled in Schedule I 

of the CSA. As such, additional 

permanent controls will not be needed 

if dipentylone is placed in Schedule II 

of the Convention on Psychotropic 

Substances, 1971. 

2-Fluorodeschloroketamine (chemical 

name: 2-(2-fluorophenyl)-2- 

(methylamino)cyclohexan-1-one), 

fluoroketamine, or 2-FDCK) is an 

arylcyclohexylamine that is related to 

ketamine and phencyclidine (PCP). 2- 

FDCK is thought to function as an Nmethyl-D-aspartate receptor antagonist 

and produce effects similar to other 

dissociative anesthetics (e.g., ketamine). 

According to anecdotal reports, these 

effects include dissociation, 

hallucination, confusion, agitation, 

stimulation, and tachycardia and 

hypertension. Studies in animals 

indicate that 2-FDCK was selfadministered (i.e., produced reinforcing 

effects) and produced a drug cue similar 

to that of ketamine. As a result, animal 

data suggests that 2-FDCK has an abuse 

potential similar to ketamine. 2-FDCK 

has not been detected in law 

enforcement seizures, or in toxicology 

screens in the United States. There are 

no commercial or approved medical 

uses for 2-FDCK, and it is not a 

controlled substance under the CSA. As 

such, additional permanent controls 

will be necessary to fulfill U.S. 

obligations if 2-FDCK is controlled 

under Schedule II of the Convention on 

Psychotropic Substances, 1971. 

Bromazolam (chemical name: 8- 

bromo-1-methyl-6-phenyl-4H- 

[1,2,4]triazolo[4,3- 

a][1,4]benzodiazepine) is a 

triazolobenzodiazepine that functions as 

a positive allosteric modulator of gaminobutyric acid A (GABAA) channels 

thereby decreasing neuronal activity. 

Similar to other benzodiazepines, such 

as alprazolam, it produces sedative and 

anxiolytic effects typically taken after 

oral administration or through injection. 

Unconfirmed anecdotal reports indicate 

that it can also produce hypnotic, 

muscle relaxant, and euphoric effects as 

well as physical dependence 

demonstrated through a withdrawal 

syndrome. Since 2021, bromazolam has 

been detected in 637 law enforcement 

seizures and has been implicated in 53 

fatalities. There are no commercial or 

approved medical uses for bromazolam 

in the United States, and it is not a 

controlled substance under the CSA. As 

such, additional permanent controls 

will be necessary to fulfill U.S. 

obligations if bromazolam is controlled 

under Schedule IV of the Convention on 

Psychotropic Substances, 1971. 

FDA, on behalf of the Secretary of 

HHS, invites interested persons to 

submit comments on the notifications 

from the United Nations concerning 

these drug substances. FDA, in 

cooperation with the National Institute 

on Drug Abuse, will consider the 

comments on behalf of HHS in 

evaluating the WHO scheduling 

recommendations. Then, under section 

201(d)(2)(B) of the CSA, HHS will 

recommend to the Secretary of State 

what position the United States should 

take when voting on the 

recommendations for control of 

substances under the 1971 Convention 

at the CND meeting in March 2024. 

Comments regarding the WHO 

recommendations for control of 

butonitazene under the 1961 Single 

Convention will also be forwarded to 

the relevant Agencies for consideration 

in developing the U.S. position 

regarding narcotic substances at the 

CND meeting. 

Dated: February 5, 2024. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2024–02573 Filed 2–7–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Cancer 

Technologies for Global Health. 

Date: February 13, 2024. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W238, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Jeffrey E. DeClue, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W238, Rockville, Maryland 

20850, 240–276–6371, decluej@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 


lotter on DSK11XQN23PROD with NOTICES1
8690 Federal Register / Vol. 89, No. 27 / Thursday, February 8, 2024 / Notices 

Dated: February 5, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02593 Filed 2–7–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

General Medical Sciences Special 

Emphasis Panel, Review of PRAT and 

K99/R00 MOCSAC Applications. March 

04, 2024, 10:30 a.m. to March 05, 2024, 

06:30 p.m., National Institute of General 

Medical Sciences, Natcher Building, 45 

Center Drive, Bethesda, Maryland, 

20892 which was published in the 

Federal Register on January 19, 2024, 

FR. Doc. 2024–00950, 89 FR 3671. 

This notice is being amended to 

change the name of the panel from 

Review of PRAT and K99/R00 MOCSAC 

Applications to the Review of PRAT and 

K99/R00 MOSAIC Applications. The 

meeting date, time, and location will 

stay the same. The meeting is closed to 

the public. 

Dated: February 2, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02582 Filed 2–7–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; SBIR contract 

topic 010. 

Date: March 15, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Nijaguna Prasad, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, 7201 

Wisconsin Avenue, Gateway Bldg., Suite 

2W200, (301) 496–9667, prasadnb@

nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: February 2, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02583 Filed 2–7–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Targeted 

Cancer Therapies. 

Date: March 4, 2024. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lawrence Ka-Yun Ng, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6152, 

MSC 7804, Bethesda, MD 20892, 301–435– 

1719, ngkl@csr.nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Chemical Synthesis and 

Biosynthesis Study Section. 

Date: March 6–7, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shan Wang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 496–4390, shan.wang@nih.gov. 

Name of Committee: Emerging 

Technologies and Training Neurosciences 

Integrated Review Group; Bioengineering of 

Neuroscience, Vision and Low Vision 

Technologies Study Section. 

Date: March 7–8, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Tina Tze-Tsang Tang, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Suite 3030, 

Bethesda, MD 20817, (301) 435–4436, tangt@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Health Services and Systems. 

Date: March 8, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mary Kate Baker, DRPH, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–5117, katie.baker2@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Computational, Modeling, and 

Biodata Management. 

Date: March 8, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Marie-Jose Belanger, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 6188, 

MSC 7804, Bethesda, MD 20892, 301–435– 

1267, belangerm@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 2, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02581 Filed 2–7–24; 8:45 am] 

BILLING CODE 4140–01–P 


lotter on DSK11XQN23PROD with NOTICES1